Table 3 Significantly enriched metabolic pathways following EP treatment in the non-injured brain
From: Metabolic-driven analytics of traumatic brain injury and neuroprotection by ethyl pyruvate
Enriched pathways | Holm | FDR | Impact | Metabolite hits |
|---|---|---|---|---|
Glycerophospholipid metabolism | 5.88E−10 | 2.94E−10 | 0.04814 | Glycerophosphocholine |
Glycine, serine and threonine metabolism | 5.98E−05 | 8.75E−06 | 0.51302 | Glycine, serine, threonine |
Glyoxylate and dicarboxylate metabolism | 5.98E−05 | 8.75E−06 | 0.1799 | Glycine, serine, citrate |
Glutathione metabolism | 5.98E−05 | 8.75E−06 | 0.08873 | Glycine |
Primary bile acid biosynthesis | 5.98E−05 | 8.75E−06 | 0.02239 | Glycine |
Lipoic acid metabolism | 5.98E−05 | 8.75E−06 | 0.0017 | Glycine |
Purine metabolism | 0.80989 | 0.14747 | 0.03277 | Adenosine-5ʹ-diphosphate, deoxyadenosine, deoxyinosine |
Pyrimidine metabolism | 0.80989 | 0.14747 | 0.0033 | Deoxycytidine |
Cysteine and methionine metabolism | 1 | 0.21211 | 0.02184 | Serine |
Lysine degradation | 1 | 0.24962 | 0.03067 | Saccaropine |
Citrate cycle (TCA cycle) | 1 | 0.61551 | 0.09038 | Citrate |